Source:http://linkedlifedata.com/resource/pubmed/id/10052892
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1999-8-9
|
pubmed:abstractText |
The in-vitro activity of HMR 3647, a novel ketolide, was investigated in comparison with those of erythromycin A, roxithromycin, clarithromycin (14-membered ring macrolides), amoxycillin-clavulanate and ciprofloxacin against 719 recent clinical Gram-positive, Gram-negative and anaerobic isolates and type cultures. HMR 3647 generally demonstrated greater activity than the other compounds with MIC90s of < or =0.5 mg/L, except for Staphylococcus epidermidis (MIC90 > 128 mg/L), Haemophilus influenzae (MIC90 = 2 mg/L), Enterococcus faecalis (MIC90 = 2 mg/L), Enterococcus faecium (MIC90 = 1 mg/L) and the anaerobes, Bacteroides fragilis (MIC90 = 2 mg/L) and Clostridium difficile (MIC90 = 1 mg/L). In general, an increase in the size of the inoculum from 10(4) to 10(6) cfu on selected strains had little effect on the MICs of HMR 3647. Additionally, the in-vitro activity of HMR 3647 was not affected by the presence of either 20 or 70% (v/v) human serum. The antichlamydial activity of HMR 3647 was generally greater than that of commonly used antichlamydial antimicrobials.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Infective Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Ciprofloxacin,
http://linkedlifedata.com/resource/pubmed/chemical/Ketolides,
http://linkedlifedata.com/resource/pubmed/chemical/Lactams,
http://linkedlifedata.com/resource/pubmed/chemical/Macrolides,
http://linkedlifedata.com/resource/pubmed/chemical/telithromycin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0305-7453
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
703-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10052892-Anti-Bacterial Agents,
pubmed-meshheading:10052892-Anti-Infective Agents,
pubmed-meshheading:10052892-Bacteria,
pubmed-meshheading:10052892-Bacterial Infections,
pubmed-meshheading:10052892-Chlamydia,
pubmed-meshheading:10052892-Chlamydia Infections,
pubmed-meshheading:10052892-Ciprofloxacin,
pubmed-meshheading:10052892-Humans,
pubmed-meshheading:10052892-Ketolides,
pubmed-meshheading:10052892-Lactams,
pubmed-meshheading:10052892-Macrolides,
pubmed-meshheading:10052892-Microbial Sensitivity Tests,
pubmed-meshheading:10052892-Serum Bactericidal Test
|
pubmed:year |
1998
|
pubmed:articleTitle |
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.
|
pubmed:affiliation |
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, UK.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|